Abstract
Background The underlying cause of central nervous system (CNS) tumors in children is largely unknown. In this nationwide, prospective population-based study we investigate rare germline variants across known and putative CPS genes and genes exhibiting evolutionary intolerance of inactivating alterations in children with CNS tumors.
Methods One hundred and twenty-eight children with CNS tumors underwent whole-genome sequencing of germline DNA. Single nucleotide and structural variants in 315 cancer related genes and 2,986 highly evolutionarily constrained genes were assessed. A systematic pedigree analysis covering 3,543 close relatives was performed.
Results Thirteen patients harbored rare pathogenic variants in nine known CPS genes. The likelihood of carrying pathogenic variants in CPS genes was higher for patients with medulloblastoma than children with other tumors (OR 5.9, CI 1.6-21.2). Metasynchronous CNS tumors were observed exclusively in children harboring pathogenic CPS gene variants (n=2, p=0.01).
In general, known pCPS genes were shown to be significantly more constrained than both genes associated with risk of adult-onset malignancies (p=5e−4) and all other genes (p=5e−17). Forty-seven patients carried 66 loss-of-functions variants in 60 constrained genes, including eight variants in six known pCPS genes. A deletion in the extremely constrained EHMT1 gene, formerly somatically linked with sonic hedgehog medulloblastoma, was found in a patient with this tumor.
Conclusions ∽10% of pediatric CNS tumors can be attributed to rare variants in known CPS genes. Analysis of evolutionarily constrained genes may increase our understanding of pediatric cancer susceptibility.
3 key points
∽10% of children with CNS tumors carry a pathogenic variant in a known cancer predisposition gene
Known pediatric-onset cancer predisposition genes show high evolutionary constraint
Loss-of-function variants in evolutionarily constrained genes may explain additional risk
Importance of this study Although CNS tumors constitute the most common form of solid neoplasms in childhood, our understanding of their underlying causes remains sparse. Predisposition studies often suffer from selection bias, lack of family and clinical data or from being limited to SNVs in established cancer predisposition genes. We report the findings of a prospective, population-based investigation of genetic predisposition to pediatric CNS tumors. Our findings illustrate that 10% of children with CNS tumors harbor a damaging alteration in a known cancer gene, of which the majority (9/13) are loss-of-function alterations. Moreover, we illustrate how recently developed knowledge on evolutionarily loss-of-function intolerant genes may be used to investigate additional pediatric cancer risk and present EHMT1 as a putative novel predisposition gene for SHH medulloblastoma. Previously undescribed links between variants in known cancer predisposition genes and specific brain tumors are presented and the importance of assessing both SV and SNV is illustrated.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is part of Childhood Oncology Network Targeting Research, Organization & Life expectancy (CONTROL) and supported by the Danish Cancer Society (R257A14720), the Danish Childhood Cancer Foundation (20195934), the Danish Childhood Brain Tumor Foundation and the European Union Interregional Oresund Kattegat Skagerrak grant. S.R. was supported by the Novo Nordisk Foundation (NNF14CC0001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Danish Capitol Region Committee on Health Research Ethics (H-15016782) and the Danish Data Protection Agency (RH-2016-219).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work is part of Childhood Oncology Network Targeting Research, Organization & Life expectancy (CONTROL) and supported by the Danish Cancer Society (R-257-A14720), the Danish Childhood Cancer Foundation (2019-5934), the Danish Childhood Brain Tumor Foundation and the European Union’s Interregional Oresund–Kattegat–Skagerrak grant. S.R. was supported by the Novo Nordisk Foundation (NNF14CC0001).
Conflicts of interest: None to declare.
Data Availability
All data produced in the present work are contained in the manuscript with the exception of genetic sequencing data. Danish legal regulation does not permit uploading of raw sequencing data. Selected data may be made available upon reasonable request (dependent on required approvals from relevant scientific ethic boards) to the authors